GBE1 Inhibition: Alternative Therapy for Lung Cancer by Altering Glucose Metabolism
Keywords:
GBE1, Hypoxia, Glycogen, NSCLC, Metabolic Reprogramming
Abstract
Lung cancer represents a neoplastic malignancy within pulmonary tissue and is associated with the highest mortality rate attributed to cancer globally. Non-Small Cell Lung Cancer (NSCLC) constitutes the predominant category of lung cancer, accounting for approximately 80-85% of all diagnosed cases, with adenocarcinoma subtyping comprising nearly 40% of NSCLC instances. Despite advancements in surgical techniques and diverse therapeutic modalities, the five-year survival rate remains below 20%, necessitating ongoing research endeavors aimed at the enhancement of lung cancer treatment paradigms. This review investigates the intricate interplay between Glycogen Branching Enzyme 1 (GBE1) and metabolic reprogramming, as well as its interaction with hypoxic environments and subsequent effects on the phenotypic characteristics of lung cancer cells. Hypoxic conditions frequently manifest in solid tumors, including lung cancer, eliciting adaptive responses such as the activation of Hypoxia-Inducible Factor-1 alpha (HIF1?), which subsequently initiates angiogenesis, induces metabolic alterations, and contributes to therapeutic resistance. Glycogen Branching Enzyme 1 (GBE1) serves as a critical enzyme involved in the synthesis of glycogen branching structures. In the context of lung adenocarcinoma (LUAD), GBE1 operates within the downstream signaling cascade of the Hypoxia-Inducible Factor-1 (HIF1) pathway. This review aspires to furnish novel insights into the pathogenesis of lung cancer and to assess the strategic targeting of the HIF1?/GBE1/NF-?B/FBP1 axis as a promising therapeutic approach for LUAD.
Downloads
Download data is not yet available.
References
Ashrafi, A., Akter, Z., Modareszadeh, P., Modareszadeh, P., Berisha, E., Alemi, P. S., Chacon Castro, M. del C., Deese, A. R., & Zhang, L. (2022). Current landscape of therapeutic resistance in lung cancer and promising strategies to overcome resistance. Cancers, 14(19), 4562.
Bao, Y., Kishnani, P., Wu, J.-Y., & Chen, Y.-T. (1996). Hepatic and neuromuscular forms of glycogen storage disease type IV caused by mutations in the same glycogen-branching enzyme gene. The Journal of Clinical Investigation, 97(4), 941–948.
Bartoszewska, S., Collawn, J. F., & Bartoszewski, R. (2022). The role of the hypoxia-related unfolded protein response (UPR) in the tumor microenvironment. Cancers, 14(19), 4870.
Bhanot, H., Reddy, M. M., Nonami, A., Weisberg, E. L., Bonal, D., Kirschmeier, P. T., Salgia, S., Podar, K., Galinsky, I., & Chowdary, T. K. (2015). Pathological glycogenesis through glycogen synthase 1 and suppression of excessive AMP kinase activity in myeloid leukemia cells. Leukemia, 29(7), 1555–1563.
Buart, S., Terry, S., Noman, M. Z., Lanoy, E., Boutros, C., Fogel, P., Dessen, P., Meurice, G., Gaston-Mathé, Y., & Vielh, P. (2017). Transcriptional response to hypoxic stress in melanoma and prognostic potential of GBE1 and BNIP3. Oncotarget, 8(65), 108786.
Cardona, A. F., Ricaurte, L., Zatarain-Barrón, Z. L., & Arrieta, O. (2020). Squamous cell lung cancer: genomic evolution and personalized therapy. Salud Pública de México, 61, 329–338.
Chalela, R., Curull, V., Enriquez, C., Pijuan, L., Bellosillo, B., & Gea, J. (2017). Lung adenocarcinoma: from molecular basis to genome-guided therapy and immunotherapy. Journal of Thoracic Disease, 9(7), 2142.
Chen, W., Li, Z., Bai, L., & Lin, Y. (2011). NF-kappaB in lung cancer, a carcinogenesis mediator and a prevention and therapy target. Front Biosci (Landmark Ed), 16(3), 1172–1185.
Chen, Zhao, Fillmore, C. M., Hammerman, P. S., Kim, C. F., & Wong, K.-K. (2014). Non-small-cell lung cancers: a heterogeneous set of diseases. Nature Reviews Cancer, 14(8), 535–546.
Chen, Zhen, Bao, H., Long, J., Zhao, P., Hu, X., Wang, H., Zhang, Y., Yang, J., Zhuge, Q., & Xia, L. (2023). GBE1 promotes glioma progression by enhancing aerobic glycolysis through inhibition of FBP1. Cancers, 15(5), 1594.
Chen, Zhou, Han, F., Du, Y., Shi, H., & Zhou, W. (2023). Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions. Signal Transduction and Targeted Therapy, 8(1), 70.
Choi, S. Y., Kang, B., Choe, J. Y., Lee, Y., Jang, H. J., Park, H.-D., Lee, S.-K., & Choe, Y. H. (2018). A case of glycogen storage disease IV with rare homozygous mutations in the glycogen branching enzyme gene. Pediatric Gastroenterology, Hepatology & Nutrition, 21(4), 365–368.
Dimitrakopoulos, F.-I. D., Kottorou, A. E., Kalofonou, M., & Kalofonos, H. P. (2020). The Fire Within: NF-?B Involvement in Non–Small Cell Lung Cancer. Cancer Research, 80(19), 4025–4036.
Dong, C., Yuan, T., Wu, Y., Wang, Y., Fan, T. W. M., Miriyala, S., Lin, Y., Yao, J., Shi, J., & Kang, T. (2013). Loss of FBP1 by Snail-mediated repression provides metabolic advantages in basal-like breast cancer. Cancer Cell, 23(3), 316–331.
Draoui, N., & Feron, O. (2011). Lactate shuttles at a glance: from physiological paradigms to anti-cancer treatments. Disease Models & Mechanisms, 4(6), 727–732.
Froese, D. S., Michaeli, A., McCorvie, T. J., Krojer, T., Sasi, M., Melaev, E., Goldblum, A., Zatsepin, M., Lossos, A., & Álvarez, R. (2015). Structural basis of glycogen branching enzyme deficiency and pharmacologic rescue by rational peptide design. Human Molecular Genetics, 24(20), 5667–5676.
Girard, N., Besada, M., Rogula, B., Lucherini, S., Vo, L., Chaudhary, M. A., Goring, S., Lozano-Ortega, G., Tran, M., & Varol, N. (2024). Comparative Efficacy of Neoadjuvant Nivolumab Plus Chemotherapy versus Conventional Comparator Treatments in Resectable Non-Small-Cell Lung Cancer: A Systematic Literature Review and Network Meta-Analysis. Cancers, 16(13), 2492.
Grootjans, J., Kaser, A., Kaufman, R. J., & Blumberg, R. S. (2016). The unfolded protein response in immunity and inflammation. Nature Reviews Immunology, 16(8), 469–484.
Hanahan, D. (2022). Hallmarks of cancer: new dimensions. Cancer Discovery, 12(1), 31–46.
Herbst, R. S., Morgensztern, D., & Boshoff, C. (2018). The biology and management of non-small cell lung cancer. Nature, 553(7689), 446–454.
Hsu, P. P., & Sabatini, D. M. (2008). Cancer cell metabolism: Warburg and beyond. Cell, 134(5), 703–707.
Hynds, R. E., Frese, K. K., Pearce, D. R., Grönroos, E., Dive, C., & Swanton, C. (2021). Progress towards non-small-cell lung cancer models that represent clinical evolutionary trajectories. Open Biology, 11(1), 200247.
Jin, W., Yao, Y., Fu, Y., Lei, X., Fu, W., Lu, Q., Tong, X., Xu, Q., Su, W., & Hu, X. (2024). WTAP/IGF2BP3-mediated GBE1 expression accelerates the proliferation and enhances stemness in pancreatic cancer cells via upregulating c-Myc. Cellular & Molecular Biology Letters, 29(1), 97.
Jin, X., Pan, Y., Wang, L., Ma, T., Zhang, L., Tang, A. H., Billadeau, D. D., Wu, H., & Huang, H. (2017). Fructose-1, 6-bisphosphatase inhibits ERK activation and bypasses gemcitabine resistance in pancreatic cancer by blocking IQGAP1–MAPK interaction. Cancer Research, 77(16), 4328–4341.
Jurisic, V., Radenkovic, S., & Konjevic, G. (2015). The actual role of LDH as tumor marker, biochemical and clinical aspects. Advances in Cancer Biomarkers: From Biochemistry to Clinic for a Critical Revision, 115–124.
Kim, J.-Y., & Lee, J.-Y. (2017). Targeting tumor adaption to chronic hypoxia: implications for drug resistance, and how it can be overcome. International Journal of Molecular Sciences, 18(9), 1854.
Lando, M., Holden, M., Bergersen, L. C., Svendsrud, D. H., Stokke, T., Sundfør, K., Glad, I. K., Kristensen, G. B., & Lyng, H. (2009). Gene dosage, expression, and ontology analysis identifies driver genes in the carcinogenesis and chemoradioresistance of cervical cancer. PLoS Genetics, 5(11), e1000719.
Lee, M., & Yoon, J.-H. (2015). Metabolic interplay between glycolysis and mitochondrial oxidation: The reverse Warburg effect and its therapeutic implication. World Journal of Biological Chemistry, 6(3), 148.
Li, B., Qiu, B., Lee, D. S. M., Walton, Z. E., Ochocki, J. D., Mathew, L. K., Mancuso, A., Gade, T. P. F., Keith, B., & Nissim, I. (2014). Fructose-1, 6-bisphosphatase opposes renal carcinoma progression. Nature, 513(7517), 251–255.
Li, C.-H., Chan, M.-H., & Chang, Y.-C. (2022). The role of fructose 1, 6-bisphosphate-mediated glycolysis/gluconeogenesis genes in cancer prognosis. Aging (Albany NY), 14(7), 3233.
Li, J., Eu, J. Q., Kong, L. R., Wang, L., Lim, Y. C., Goh, B. C., & Wong, A. L. A. (2020). Targeting metabolism in cancer cells and the tumour microenvironment for cancer therapy. Molecules, 25(20), 4831.
Li, L., Lu, J., Xue, W., Wang, L., Zhai, Y., Fan, Z., Wu, G., Fan, F., Li, J., & Zhang, C. (2017). Target of obstructive sleep apnea syndrome merge lung cancer: based on big data platform. Oncotarget, 8(13), 21567.
Li, L., Yang, L., Cheng, S., Fan, Z., Shen, Z., Xue, W., Zheng, Y., Li, F., Wang, D., & Zhang, K. (2019). Lung adenocarcinoma-intrinsic GBE1 signaling inhibits anti-tumor immunity. Molecular Cancer, 18, 1–16.
Li, L., Yang, L., Fan, Z., Xue, W., Shen, Z., Yuan, Y., Sun, X., Wang, D., Lian, J., & Wang, L. (2020). Hypoxia-induced GBE1 expression promotes tumor progression through metabolic reprogramming in lung adenocarcinoma. Signal Transduction and Targeted Therapy, 5(1), 54.
Li, Y., Zhao, L., & Li, X.-F. (2021). Hypoxia and the tumor microenvironment. Technology in Cancer Research & Treatment, 20, 15330338211036304.
Li, Z., Cui, Y., Zhang, S., Xu, J., Shao, J., Chen, H., Chen, J., Wang, S., Zeng, M., & Zhang, H. (2023). Novel hypoxia-related gene signature for predicting prognoses that correlate with the tumor immune microenvironment in NSCLC. Frontiers in Genetics, 14, 1115308.
Liang, Y., Lei, Y., Liang, M., Du, M., Liu, Z., Li, X., Meng, X., Zhou, B., & Gao, Y. (2022). GBE1 is an independent prognostic marker and associated with CD163+ tumor-associated macrophage infiltration in lung adenocarcinoma. Frontiers in Oncology, 11, 781344.
Liu, C., Jin, Y., & Fan, Z. (2021). The mechanism of Warburg effect-induced chemoresistance in cancer. Frontiers in Oncology, 11, 698023.
Liu, G.-M., Li, Q., Zhang, P.-F., Shen, S.-L., Xie, W.-X., Chen, B., Wu, J., Hu, W.-J., Huang, X.-Y., & Peng, B.-G. (2018). Restoration of FBP1 suppressed Snail-induced epithelial to mesenchymal transition in hepatocellular carcinoma. Cell Death & Disease, 9(11), 1132.
Liu, X., Wang, X., Zhang, J., Lam, E. K. Y., Shin, V. Y., Cheng, A. S. L., Yu, J., Chan, F. K. L., Sung, J. J. Y., & Jin, H. C. (2010). Warburg effect revisited: an epigenetic link between glycolysis and gastric carcinogenesis. Oncogene, 29(3), 442–450.
Lu, C., Ren, C., Yang, T., Sun, Y., Qiao, P., Han, X., & Yu, Z. (2020). Fructose-1, 6-bisphosphatase 1 interacts with NF-?B p65 to regulate breast tumorigenesis via PIM2 induced phosphorylation. Theranostics, 10(19), 8606.
Ma, L., & Zong, X. (2020). Metabolic symbiosis in chemoresistance: refocusing the role of aerobic glycolysis. Frontiers in Oncology, 10, 5.
Ma, Z., Xiang, X., Li, S., Xie, P., Gong, Q., Goh, B.-C., & Wang, L. (2022). Targeting hypoxia-inducible factor-1, for cancer treatment: Recent advances in developing small-molecule inhibitors from natural compounds. Seminars in Cancer Biology, 80, 379–390.
Mafi, S., Ahmadi, E., Meehan, E., Chiari, C., Mansoori, B., Sadeghi, H., Milani, S., Jafarinia, M., Taeb, S., & Mafakheri Bashmagh, B. (2023). The mTOR signaling pathway interacts with the ER stress response and the unfolded protein response in cancer. Cancer Research, 83(15), 2450–2460.
Marín?Hernández, A., Rodríguez?Enríquez, S., Vital?González, P. A., Flores?Rodríguez, F. L., Macías?Silva, M., Sosa?Garrocho, M., & Moreno?Sánchez, R. (2006). Determining and understanding the control of glycolysis in fast?growth tumor cells: Flux control by an over?expressed but strongly product?inhibited hexokinase. The FEBS Journal, 273(9), 1975–1988.
Maruggi, M., Layng, F. I., Lemos Jr, R., Garcia, G., James, B. P., Sevilla, M., Soldevilla, F., Baaten, B. J., de Jong, P. R., & Koh, M. Y. (2019). Absence of HIF1A leads to glycogen accumulation and an inflammatory response that enables pancreatic tumor growth. Cancer Research, 79(22), 5839–5848.
Masoud, G. N., & Li, W. (2015). HIF-1? pathway: role, regulation and intervention for cancer therapy. Acta Pharmaceutica Sinica B, 5(5), 378–389.
Melendez, R., Melendez-Hevia, E., & Canela, E. I. (1999). The fractal structure of glycogen: a clever solution to optimize cell metabolism. Biophysical Journal, 77(3), 1327–1332.
Mittal, V., El Rayes, T., Narula, N., McGraw, T. E., Altorki, N. K., & Barcellos-Hoff, M. H. (2016). The microenvironment of lung cancer and therapeutic implications. Lung Cancer and Personalized Medicine: Novel Therapies and Clinical Management, 75–110.
Mujcic, H., Rzymski, T., Rouschop, K. M. A., Koritzinsky, M., Milani, M., Harris, A. L., & Wouters, B. G. (2009). Hypoxic activation of the unfolded protein response (UPR) induces expression of the metastasis-associated gene LAMP3. Radiotherapy and Oncology, 92(3), 450–459.
Nisar, H., Sanchidrián González, P. M., Brauny, M., Labonté, F. M., Schmitz, C., Roggan, M. D., Konda, B., & Hellweg, C. E. (2023). Hypoxia Changes Energy Metabolism and Growth Rate in Non-Small Cell Lung Cancer Cells. Cancers, 15(9), 2472.
Noman, M. Z., Hasmim, M., Messai, Y., Terry, S., Kieda, C., Janji, B., & Chouaib, S. (2015). Hypoxia: a key player in antitumor immune response. A review in the theme: cellular responses to hypoxia. American Journal of Physiology-Cell Physiology, 309(9), C569–C579.
Oser, M. G., Niederst, M. J., Sequist, L. V, & Engelman, J. A. (2015). Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin. The Lancet Oncology, 16(4), e165–e172.
Pavlova, N. N., Zhu, J., & Thompson, C. B. (2022). The hallmarks of cancer metabolism: Still emerging. Cell Metabolism, 34(3), 355–377.
Petersen, M. C., Vatner, D. F., & Shulman, G. I. (2017). Regulation of hepatic glucose metabolism in health and disease. Nature Reviews Endocrinology, 13(10), 572–587.
Pugachev, A., Ruan, S., Carlin, S., Larson, S. M., Campa, J., Ling, C. C., & Humm, J. L. (2005). Dependence of FDG uptake on tumor microenvironment. International Journal of Radiation Oncology* Biology* Physics, 62(2), 545–553.
Rasmi, R. R., Sakthivel, K. M., & Guruvayoorappan, C. (2020). NF-?B inhibitors in treatment and prevention of lung cancer. Biomedicine & Pharmacotherapy, 130, 110569.
Rattigan, Y. I., Patel, B. B., Ackerstaff, E., Sukenick, G., Koutcher, J. A., Glod, J. W., & Banerjee, D. (2012). Lactate is a mediator of metabolic cooperation between stromal carcinoma associated fibroblasts and glycolytic tumor cells in the tumor microenvironment. Experimental Cell Research, 318(4), 326–335.
Saito, M., Suzuki, H., Kono, K., Takenoshita, S., & Kohno, T. (2018). Treatment of lung adenocarcinoma by molecular-targeted therapy and immunotherapy. Surgery Today, 48, 1–8.
Sánchez-Ortega, M., Carrera, A. C., & Garrido, A. (2021). Role of NRF2 in lung cancer. Cells, 10(8), 1879.
Semenza, G. L. (2013). HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations. The Journal of Clinical Investigation, 123(9), 3664–3671.
Shen, B., Huang, T., Sun, Y., Jin, Z., & Li, X.-F. (2017). Revisit 18F-fluorodeoxyglucose oncology positron emission tomography:“systems molecular imaging” of glucose metabolism. Oncotarget, 8(26), 43536.
Shi, L., He, C., Li, Z., Wang, Z., & Zhang, Q. (2017). FBP1 modulates cell metabolism of breast cancer cells by inhibiting the expression of HIF-1?. Neoplasma, 64(4), 535–542.
Stine, Z. E., Altman, B. J., Hsieh, A. L., Gouw, A. M., & Dang, C. V. (2014). Deregulation of the cellular energetics of cancer cells. In Pathobiology of human disease: a dynamic encyclopedia of disease mechanisms (pp. 444–455). Elsevier Inc.
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021). Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 71(3), 209–249.
Thon, V. J., Khalil, M., & Cannon, J. F. (1993). Isolation of human glycogen branching enzyme cDNAs by screening complementation in yeast. Journal of Biological Chemistry, 268(10), 7509–7513.
Vernia, S., Rubio, T., Heredia, M., de Córdoba, S. R., & Sanz, P. (2009). Increased endoplasmic reticulum stress and decreased proteasomal function in lafora disease models lacking the phosphatase laforin. PloS One, 4(6), e5907.
Wanandi, S. I., Ningsih, S. S., Asikin, H., Hosea, R., & Neolaka, G. M. G. (2018). Metabolic interplay between tumour cells and cancer-associated fibroblasts (CAFs) under hypoxia versus normoxia. The Malaysian Journal of Medical Sciences: MJMS, 25(3), 7.
Wang, R. (2022). Lung Adenocarcinoma treatment: Traditional therapy and Immunotherapy. Highlights in Science, Engineering and Technology, 14, 350–354.
Warburg, O. (1956). On the origin of cancer cells. Science, 123(3191), 309–314.
Yan, Y., Wang, L.-F., & Wang, R.-F. (2015). Role of cancer-associated fibroblasts in invasion and metastasis of gastric cancer. World Journal of Gastroenterology: WJG, 21(33), 9717.
Yoshida, G. J. (2015). Metabolic reprogramming: the emerging concept and associated therapeutic strategies. Journal of Experimental & Clinical Cancer Research, 34, 1–10.
Yuan, A. N. G., Yang, P.-C., Yu, C.-J., Chen, W.-J., Lin, F.-Y., Kuo, S.-H., & Luh, K.-T. (2000). Interleukin-8 messenger ribonucleic acid expression correlates with tumor progression, tumor angiogenesis, patient survival, and timing of relapse in non–small-cell lung cancer. American Journal of Respiratory and Critical Care Medicine, 162(5), 1957–1963.
Zappa, C., & Mousa, S. A. (2016). Non-small cell lung cancer: current treatment and future advances. Translational Lung Cancer Research, 5(3), 288.
Zhang, G., Li, J., Wang, X., Ma, Y., Yin, X., Wang, F., Zheng, H., Duan, X., Postel, G. C., & Li, X.-F. (2015). The reverse Warburg effect and 18F-FDG uptake in non–small cell lung cancer A549 in mice: a pilot study. Journal of Nuclear Medicine, 56(4), 607–612.
Zhang, J., Wang, J., Xing, H., Li, Q., Zhao, Q., & Li, J. (2016). Down-regulation of FBP1 by ZEB1-mediated repression confers to growth and invasion in lung cancer cells. Molecular and Cellular Biochemistry, 411, 331–340.
Zhang, L., Ludden, C. M., Cullen, A. J., Tew, K. D., de Barros, A. L. B., & Townsend, D. M. (2023). Nuclear factor kappa B expression in non-small cell lung cancer. Biomedicine & Pharmacotherapy, 167, 115459.
Zhu, Y., Shi, M., Chen, H., Gu, J., Zhang, J., Shen, B., Deng, X., Xie, J., Zhan, X., & Peng, C. (2015). NPM1 activates metabolic changes by inhibiting FBP1 while promoting the tumorigenicity of pancreatic cancer cells. Oncotarget, 6(25), 21443.
Zió?kowska-Suchanek, I. (2021). Mimicking tumor hypoxia in non-small cell lung cancer employing three-dimensional in vitro models. Cells, 10(1), 141.
Bao, Y., Kishnani, P., Wu, J.-Y., & Chen, Y.-T. (1996). Hepatic and neuromuscular forms of glycogen storage disease type IV caused by mutations in the same glycogen-branching enzyme gene. The Journal of Clinical Investigation, 97(4), 941–948.
Bartoszewska, S., Collawn, J. F., & Bartoszewski, R. (2022). The role of the hypoxia-related unfolded protein response (UPR) in the tumor microenvironment. Cancers, 14(19), 4870.
Bhanot, H., Reddy, M. M., Nonami, A., Weisberg, E. L., Bonal, D., Kirschmeier, P. T., Salgia, S., Podar, K., Galinsky, I., & Chowdary, T. K. (2015). Pathological glycogenesis through glycogen synthase 1 and suppression of excessive AMP kinase activity in myeloid leukemia cells. Leukemia, 29(7), 1555–1563.
Buart, S., Terry, S., Noman, M. Z., Lanoy, E., Boutros, C., Fogel, P., Dessen, P., Meurice, G., Gaston-Mathé, Y., & Vielh, P. (2017). Transcriptional response to hypoxic stress in melanoma and prognostic potential of GBE1 and BNIP3. Oncotarget, 8(65), 108786.
Cardona, A. F., Ricaurte, L., Zatarain-Barrón, Z. L., & Arrieta, O. (2020). Squamous cell lung cancer: genomic evolution and personalized therapy. Salud Pública de México, 61, 329–338.
Chalela, R., Curull, V., Enriquez, C., Pijuan, L., Bellosillo, B., & Gea, J. (2017). Lung adenocarcinoma: from molecular basis to genome-guided therapy and immunotherapy. Journal of Thoracic Disease, 9(7), 2142.
Chen, W., Li, Z., Bai, L., & Lin, Y. (2011). NF-kappaB in lung cancer, a carcinogenesis mediator and a prevention and therapy target. Front Biosci (Landmark Ed), 16(3), 1172–1185.
Chen, Zhao, Fillmore, C. M., Hammerman, P. S., Kim, C. F., & Wong, K.-K. (2014). Non-small-cell lung cancers: a heterogeneous set of diseases. Nature Reviews Cancer, 14(8), 535–546.
Chen, Zhen, Bao, H., Long, J., Zhao, P., Hu, X., Wang, H., Zhang, Y., Yang, J., Zhuge, Q., & Xia, L. (2023). GBE1 promotes glioma progression by enhancing aerobic glycolysis through inhibition of FBP1. Cancers, 15(5), 1594.
Chen, Zhou, Han, F., Du, Y., Shi, H., & Zhou, W. (2023). Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions. Signal Transduction and Targeted Therapy, 8(1), 70.
Choi, S. Y., Kang, B., Choe, J. Y., Lee, Y., Jang, H. J., Park, H.-D., Lee, S.-K., & Choe, Y. H. (2018). A case of glycogen storage disease IV with rare homozygous mutations in the glycogen branching enzyme gene. Pediatric Gastroenterology, Hepatology & Nutrition, 21(4), 365–368.
Dimitrakopoulos, F.-I. D., Kottorou, A. E., Kalofonou, M., & Kalofonos, H. P. (2020). The Fire Within: NF-?B Involvement in Non–Small Cell Lung Cancer. Cancer Research, 80(19), 4025–4036.
Dong, C., Yuan, T., Wu, Y., Wang, Y., Fan, T. W. M., Miriyala, S., Lin, Y., Yao, J., Shi, J., & Kang, T. (2013). Loss of FBP1 by Snail-mediated repression provides metabolic advantages in basal-like breast cancer. Cancer Cell, 23(3), 316–331.
Draoui, N., & Feron, O. (2011). Lactate shuttles at a glance: from physiological paradigms to anti-cancer treatments. Disease Models & Mechanisms, 4(6), 727–732.
Froese, D. S., Michaeli, A., McCorvie, T. J., Krojer, T., Sasi, M., Melaev, E., Goldblum, A., Zatsepin, M., Lossos, A., & Álvarez, R. (2015). Structural basis of glycogen branching enzyme deficiency and pharmacologic rescue by rational peptide design. Human Molecular Genetics, 24(20), 5667–5676.
Girard, N., Besada, M., Rogula, B., Lucherini, S., Vo, L., Chaudhary, M. A., Goring, S., Lozano-Ortega, G., Tran, M., & Varol, N. (2024). Comparative Efficacy of Neoadjuvant Nivolumab Plus Chemotherapy versus Conventional Comparator Treatments in Resectable Non-Small-Cell Lung Cancer: A Systematic Literature Review and Network Meta-Analysis. Cancers, 16(13), 2492.
Grootjans, J., Kaser, A., Kaufman, R. J., & Blumberg, R. S. (2016). The unfolded protein response in immunity and inflammation. Nature Reviews Immunology, 16(8), 469–484.
Hanahan, D. (2022). Hallmarks of cancer: new dimensions. Cancer Discovery, 12(1), 31–46.
Herbst, R. S., Morgensztern, D., & Boshoff, C. (2018). The biology and management of non-small cell lung cancer. Nature, 553(7689), 446–454.
Hsu, P. P., & Sabatini, D. M. (2008). Cancer cell metabolism: Warburg and beyond. Cell, 134(5), 703–707.
Hynds, R. E., Frese, K. K., Pearce, D. R., Grönroos, E., Dive, C., & Swanton, C. (2021). Progress towards non-small-cell lung cancer models that represent clinical evolutionary trajectories. Open Biology, 11(1), 200247.
Jin, W., Yao, Y., Fu, Y., Lei, X., Fu, W., Lu, Q., Tong, X., Xu, Q., Su, W., & Hu, X. (2024). WTAP/IGF2BP3-mediated GBE1 expression accelerates the proliferation and enhances stemness in pancreatic cancer cells via upregulating c-Myc. Cellular & Molecular Biology Letters, 29(1), 97.
Jin, X., Pan, Y., Wang, L., Ma, T., Zhang, L., Tang, A. H., Billadeau, D. D., Wu, H., & Huang, H. (2017). Fructose-1, 6-bisphosphatase inhibits ERK activation and bypasses gemcitabine resistance in pancreatic cancer by blocking IQGAP1–MAPK interaction. Cancer Research, 77(16), 4328–4341.
Jurisic, V., Radenkovic, S., & Konjevic, G. (2015). The actual role of LDH as tumor marker, biochemical and clinical aspects. Advances in Cancer Biomarkers: From Biochemistry to Clinic for a Critical Revision, 115–124.
Kim, J.-Y., & Lee, J.-Y. (2017). Targeting tumor adaption to chronic hypoxia: implications for drug resistance, and how it can be overcome. International Journal of Molecular Sciences, 18(9), 1854.
Lando, M., Holden, M., Bergersen, L. C., Svendsrud, D. H., Stokke, T., Sundfør, K., Glad, I. K., Kristensen, G. B., & Lyng, H. (2009). Gene dosage, expression, and ontology analysis identifies driver genes in the carcinogenesis and chemoradioresistance of cervical cancer. PLoS Genetics, 5(11), e1000719.
Lee, M., & Yoon, J.-H. (2015). Metabolic interplay between glycolysis and mitochondrial oxidation: The reverse Warburg effect and its therapeutic implication. World Journal of Biological Chemistry, 6(3), 148.
Li, B., Qiu, B., Lee, D. S. M., Walton, Z. E., Ochocki, J. D., Mathew, L. K., Mancuso, A., Gade, T. P. F., Keith, B., & Nissim, I. (2014). Fructose-1, 6-bisphosphatase opposes renal carcinoma progression. Nature, 513(7517), 251–255.
Li, C.-H., Chan, M.-H., & Chang, Y.-C. (2022). The role of fructose 1, 6-bisphosphate-mediated glycolysis/gluconeogenesis genes in cancer prognosis. Aging (Albany NY), 14(7), 3233.
Li, J., Eu, J. Q., Kong, L. R., Wang, L., Lim, Y. C., Goh, B. C., & Wong, A. L. A. (2020). Targeting metabolism in cancer cells and the tumour microenvironment for cancer therapy. Molecules, 25(20), 4831.
Li, L., Lu, J., Xue, W., Wang, L., Zhai, Y., Fan, Z., Wu, G., Fan, F., Li, J., & Zhang, C. (2017). Target of obstructive sleep apnea syndrome merge lung cancer: based on big data platform. Oncotarget, 8(13), 21567.
Li, L., Yang, L., Cheng, S., Fan, Z., Shen, Z., Xue, W., Zheng, Y., Li, F., Wang, D., & Zhang, K. (2019). Lung adenocarcinoma-intrinsic GBE1 signaling inhibits anti-tumor immunity. Molecular Cancer, 18, 1–16.
Li, L., Yang, L., Fan, Z., Xue, W., Shen, Z., Yuan, Y., Sun, X., Wang, D., Lian, J., & Wang, L. (2020). Hypoxia-induced GBE1 expression promotes tumor progression through metabolic reprogramming in lung adenocarcinoma. Signal Transduction and Targeted Therapy, 5(1), 54.
Li, Y., Zhao, L., & Li, X.-F. (2021). Hypoxia and the tumor microenvironment. Technology in Cancer Research & Treatment, 20, 15330338211036304.
Li, Z., Cui, Y., Zhang, S., Xu, J., Shao, J., Chen, H., Chen, J., Wang, S., Zeng, M., & Zhang, H. (2023). Novel hypoxia-related gene signature for predicting prognoses that correlate with the tumor immune microenvironment in NSCLC. Frontiers in Genetics, 14, 1115308.
Liang, Y., Lei, Y., Liang, M., Du, M., Liu, Z., Li, X., Meng, X., Zhou, B., & Gao, Y. (2022). GBE1 is an independent prognostic marker and associated with CD163+ tumor-associated macrophage infiltration in lung adenocarcinoma. Frontiers in Oncology, 11, 781344.
Liu, C., Jin, Y., & Fan, Z. (2021). The mechanism of Warburg effect-induced chemoresistance in cancer. Frontiers in Oncology, 11, 698023.
Liu, G.-M., Li, Q., Zhang, P.-F., Shen, S.-L., Xie, W.-X., Chen, B., Wu, J., Hu, W.-J., Huang, X.-Y., & Peng, B.-G. (2018). Restoration of FBP1 suppressed Snail-induced epithelial to mesenchymal transition in hepatocellular carcinoma. Cell Death & Disease, 9(11), 1132.
Liu, X., Wang, X., Zhang, J., Lam, E. K. Y., Shin, V. Y., Cheng, A. S. L., Yu, J., Chan, F. K. L., Sung, J. J. Y., & Jin, H. C. (2010). Warburg effect revisited: an epigenetic link between glycolysis and gastric carcinogenesis. Oncogene, 29(3), 442–450.
Lu, C., Ren, C., Yang, T., Sun, Y., Qiao, P., Han, X., & Yu, Z. (2020). Fructose-1, 6-bisphosphatase 1 interacts with NF-?B p65 to regulate breast tumorigenesis via PIM2 induced phosphorylation. Theranostics, 10(19), 8606.
Ma, L., & Zong, X. (2020). Metabolic symbiosis in chemoresistance: refocusing the role of aerobic glycolysis. Frontiers in Oncology, 10, 5.
Ma, Z., Xiang, X., Li, S., Xie, P., Gong, Q., Goh, B.-C., & Wang, L. (2022). Targeting hypoxia-inducible factor-1, for cancer treatment: Recent advances in developing small-molecule inhibitors from natural compounds. Seminars in Cancer Biology, 80, 379–390.
Mafi, S., Ahmadi, E., Meehan, E., Chiari, C., Mansoori, B., Sadeghi, H., Milani, S., Jafarinia, M., Taeb, S., & Mafakheri Bashmagh, B. (2023). The mTOR signaling pathway interacts with the ER stress response and the unfolded protein response in cancer. Cancer Research, 83(15), 2450–2460.
Marín?Hernández, A., Rodríguez?Enríquez, S., Vital?González, P. A., Flores?Rodríguez, F. L., Macías?Silva, M., Sosa?Garrocho, M., & Moreno?Sánchez, R. (2006). Determining and understanding the control of glycolysis in fast?growth tumor cells: Flux control by an over?expressed but strongly product?inhibited hexokinase. The FEBS Journal, 273(9), 1975–1988.
Maruggi, M., Layng, F. I., Lemos Jr, R., Garcia, G., James, B. P., Sevilla, M., Soldevilla, F., Baaten, B. J., de Jong, P. R., & Koh, M. Y. (2019). Absence of HIF1A leads to glycogen accumulation and an inflammatory response that enables pancreatic tumor growth. Cancer Research, 79(22), 5839–5848.
Masoud, G. N., & Li, W. (2015). HIF-1? pathway: role, regulation and intervention for cancer therapy. Acta Pharmaceutica Sinica B, 5(5), 378–389.
Melendez, R., Melendez-Hevia, E., & Canela, E. I. (1999). The fractal structure of glycogen: a clever solution to optimize cell metabolism. Biophysical Journal, 77(3), 1327–1332.
Mittal, V., El Rayes, T., Narula, N., McGraw, T. E., Altorki, N. K., & Barcellos-Hoff, M. H. (2016). The microenvironment of lung cancer and therapeutic implications. Lung Cancer and Personalized Medicine: Novel Therapies and Clinical Management, 75–110.
Mujcic, H., Rzymski, T., Rouschop, K. M. A., Koritzinsky, M., Milani, M., Harris, A. L., & Wouters, B. G. (2009). Hypoxic activation of the unfolded protein response (UPR) induces expression of the metastasis-associated gene LAMP3. Radiotherapy and Oncology, 92(3), 450–459.
Nisar, H., Sanchidrián González, P. M., Brauny, M., Labonté, F. M., Schmitz, C., Roggan, M. D., Konda, B., & Hellweg, C. E. (2023). Hypoxia Changes Energy Metabolism and Growth Rate in Non-Small Cell Lung Cancer Cells. Cancers, 15(9), 2472.
Noman, M. Z., Hasmim, M., Messai, Y., Terry, S., Kieda, C., Janji, B., & Chouaib, S. (2015). Hypoxia: a key player in antitumor immune response. A review in the theme: cellular responses to hypoxia. American Journal of Physiology-Cell Physiology, 309(9), C569–C579.
Oser, M. G., Niederst, M. J., Sequist, L. V, & Engelman, J. A. (2015). Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin. The Lancet Oncology, 16(4), e165–e172.
Pavlova, N. N., Zhu, J., & Thompson, C. B. (2022). The hallmarks of cancer metabolism: Still emerging. Cell Metabolism, 34(3), 355–377.
Petersen, M. C., Vatner, D. F., & Shulman, G. I. (2017). Regulation of hepatic glucose metabolism in health and disease. Nature Reviews Endocrinology, 13(10), 572–587.
Pugachev, A., Ruan, S., Carlin, S., Larson, S. M., Campa, J., Ling, C. C., & Humm, J. L. (2005). Dependence of FDG uptake on tumor microenvironment. International Journal of Radiation Oncology* Biology* Physics, 62(2), 545–553.
Rasmi, R. R., Sakthivel, K. M., & Guruvayoorappan, C. (2020). NF-?B inhibitors in treatment and prevention of lung cancer. Biomedicine & Pharmacotherapy, 130, 110569.
Rattigan, Y. I., Patel, B. B., Ackerstaff, E., Sukenick, G., Koutcher, J. A., Glod, J. W., & Banerjee, D. (2012). Lactate is a mediator of metabolic cooperation between stromal carcinoma associated fibroblasts and glycolytic tumor cells in the tumor microenvironment. Experimental Cell Research, 318(4), 326–335.
Saito, M., Suzuki, H., Kono, K., Takenoshita, S., & Kohno, T. (2018). Treatment of lung adenocarcinoma by molecular-targeted therapy and immunotherapy. Surgery Today, 48, 1–8.
Sánchez-Ortega, M., Carrera, A. C., & Garrido, A. (2021). Role of NRF2 in lung cancer. Cells, 10(8), 1879.
Semenza, G. L. (2013). HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations. The Journal of Clinical Investigation, 123(9), 3664–3671.
Shen, B., Huang, T., Sun, Y., Jin, Z., & Li, X.-F. (2017). Revisit 18F-fluorodeoxyglucose oncology positron emission tomography:“systems molecular imaging” of glucose metabolism. Oncotarget, 8(26), 43536.
Shi, L., He, C., Li, Z., Wang, Z., & Zhang, Q. (2017). FBP1 modulates cell metabolism of breast cancer cells by inhibiting the expression of HIF-1?. Neoplasma, 64(4), 535–542.
Stine, Z. E., Altman, B. J., Hsieh, A. L., Gouw, A. M., & Dang, C. V. (2014). Deregulation of the cellular energetics of cancer cells. In Pathobiology of human disease: a dynamic encyclopedia of disease mechanisms (pp. 444–455). Elsevier Inc.
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021). Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 71(3), 209–249.
Thon, V. J., Khalil, M., & Cannon, J. F. (1993). Isolation of human glycogen branching enzyme cDNAs by screening complementation in yeast. Journal of Biological Chemistry, 268(10), 7509–7513.
Vernia, S., Rubio, T., Heredia, M., de Córdoba, S. R., & Sanz, P. (2009). Increased endoplasmic reticulum stress and decreased proteasomal function in lafora disease models lacking the phosphatase laforin. PloS One, 4(6), e5907.
Wanandi, S. I., Ningsih, S. S., Asikin, H., Hosea, R., & Neolaka, G. M. G. (2018). Metabolic interplay between tumour cells and cancer-associated fibroblasts (CAFs) under hypoxia versus normoxia. The Malaysian Journal of Medical Sciences: MJMS, 25(3), 7.
Wang, R. (2022). Lung Adenocarcinoma treatment: Traditional therapy and Immunotherapy. Highlights in Science, Engineering and Technology, 14, 350–354.
Warburg, O. (1956). On the origin of cancer cells. Science, 123(3191), 309–314.
Yan, Y., Wang, L.-F., & Wang, R.-F. (2015). Role of cancer-associated fibroblasts in invasion and metastasis of gastric cancer. World Journal of Gastroenterology: WJG, 21(33), 9717.
Yoshida, G. J. (2015). Metabolic reprogramming: the emerging concept and associated therapeutic strategies. Journal of Experimental & Clinical Cancer Research, 34, 1–10.
Yuan, A. N. G., Yang, P.-C., Yu, C.-J., Chen, W.-J., Lin, F.-Y., Kuo, S.-H., & Luh, K.-T. (2000). Interleukin-8 messenger ribonucleic acid expression correlates with tumor progression, tumor angiogenesis, patient survival, and timing of relapse in non–small-cell lung cancer. American Journal of Respiratory and Critical Care Medicine, 162(5), 1957–1963.
Zappa, C., & Mousa, S. A. (2016). Non-small cell lung cancer: current treatment and future advances. Translational Lung Cancer Research, 5(3), 288.
Zhang, G., Li, J., Wang, X., Ma, Y., Yin, X., Wang, F., Zheng, H., Duan, X., Postel, G. C., & Li, X.-F. (2015). The reverse Warburg effect and 18F-FDG uptake in non–small cell lung cancer A549 in mice: a pilot study. Journal of Nuclear Medicine, 56(4), 607–612.
Zhang, J., Wang, J., Xing, H., Li, Q., Zhao, Q., & Li, J. (2016). Down-regulation of FBP1 by ZEB1-mediated repression confers to growth and invasion in lung cancer cells. Molecular and Cellular Biochemistry, 411, 331–340.
Zhang, L., Ludden, C. M., Cullen, A. J., Tew, K. D., de Barros, A. L. B., & Townsend, D. M. (2023). Nuclear factor kappa B expression in non-small cell lung cancer. Biomedicine & Pharmacotherapy, 167, 115459.
Zhu, Y., Shi, M., Chen, H., Gu, J., Zhang, J., Shen, B., Deng, X., Xie, J., Zhan, X., & Peng, C. (2015). NPM1 activates metabolic changes by inhibiting FBP1 while promoting the tumorigenicity of pancreatic cancer cells. Oncotarget, 6(25), 21443.
Zió?kowska-Suchanek, I. (2021). Mimicking tumor hypoxia in non-small cell lung cancer employing three-dimensional in vitro models. Cells, 10(1), 141.
Published
2025-03-15
Section
Original Articles
Copyright (c) 2025 Anisa Istiqomah, Yulia Ariani, Dwi Ari Pujianto
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
